From program suspension to the pandemic: A qualitative examination of Australia’s vaccine pharmacovigilance system over 10 years
Vaccine·
- DOI
- 10.1016/j.vaccine.2021.07.059
- PMID
- 34376308
- PMCID
- PMC8445694
- OpenAlex
- W3191152922
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings address readiness for COVID-19 vaccine safety monitoring and identify opportunities to enhance pharmacovigilance systems that could contribute to both local and global vaccine safety surveillance. Transparent communication was emphasized as essential for addressing vaccine safety concerns during the pandemic.
Structured evidence summary
Research question
The study evaluated expert views on Australia's vaccine pharmacovigilance system capacity to detect, examine, and communicate safety signals, conducted in advance of COVID-19 vaccine rollout and ten years after the 2010 seasonal influenza vaccine suspension in children.
Study design
Qualitative study using semi-structured interviews with seventeen vaccine safety experts in Australia, conducted between July and October 2020. Thematic analysis applied a deductive coding approach to verbatim transcripts guided by Australian and international frameworks.
Population and setting
Seventeen individuals with vaccine safety expertise in Australia were interviewed. The evaluation took place in the context of Australia's national vaccine pharmacovigilance system, referencing a 2010 program suspension for children under five years and preparations for COVID-19 immunization.
Main findings
Participants described improvements and innovation in Australia's vaccine pharmacovigilance over the decade, particularly through a new active cohort event monitoring system using SMS surveys. Experts expressed confidence in the system's foundation for COVID-19 vaccine safety surveillance and identified the pandemic program as a driver for further enhancement through better integration of active and spontaneous reporting systems, population-level active surveillance via data linkage, and transparent communication.
Public-health relevance
The findings address readiness for COVID-19 vaccine safety monitoring and identify opportunities to enhance pharmacovigilance systems that could contribute to both local and global vaccine safety surveillance. Transparent communication was emphasized as essential for addressing vaccine safety concerns during the pandemic.
Important limitations
This summary relies on the supplied single-article abstract and metadata. Access to the full paper is required for decision-grade interpretation, including details on participant selection, interview methodology, and complete thematic findings.
GIDS interpretation
This article was classified under surveillance, vaccination, and vaccine safety topics with links to COVID-19, influenza, and Australia. It describes expert perspectives on pharmacovigilance system capacity rather than reporting a specific safety signal. The paper provides context on system readiness and enhancement opportunities identified before COVID-19 vaccine deployment.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 13 auditable classifier relationships to diseases, places, topics, and study design.